Cosmeceuticals During COVID: New Natural Infusions, Same Regulatory Jungle
The Pandemic, Clean Beauty Demand Drive Innovation At Cosmetic/Drug Borderline
Consumers with time on their hands at home have become better researched about plant-derived ingredients that deliver results, which, according to Lodaat Pharmaceuticals, is where cosmeceuticals are headed. Cosmeceutical possibilities and regulatory complexities were the substance of a panel discussion at CPhI Worldwide, featuring Lodaat director Rajiv Khatau and EAS Consulting’s John Bailey.
You may also be interested in...
The Personal Care Products Safety Act was reintroduced in the US Senate on 17 June with industry support including leading brands at big-name multinationals. The latest “Feinstein bill” for modernizing US cosmetics regulations purports to strengthen counterfeit product protections while floating additional requirements for fragrance allergen labeling and banning intentionally added PFAS.
The online universe is abuzz with complaints about 2016, with some ready to dub the year “worst ever.” It certainly was a rough one for anti-aging skin-care marketers, and while FDA’s warning letter activity has declined of late, consumer lawsuits continue to file challenging companies’ clock-reversing promises.
A key component of FDA’s enforcement strategy in the cosmetics space is monitoring companies’ websites for overreaching product claims and issuing warning letters accordingly. Examination of past offenders’ current sites and updated claims offers potential visibility into language the agency will and will not tolerate when it comes to promoting skin-care benefits.